glp _1 GLP-1 Formula *These statements have not been evaluated by the Food and Drug Administration (FDA) GLP-1 Supplement Support, GLP Activate

The statements made within this website have not been evaluated by the US Food and Drug Administration

Plaintiffs in the litigation report experiencing these specific digestive system complications: Gastroparesis (stomach paralysis): The most common injury alleged in lawsuits, this condition involves partial or complete paralysis of stomach muscles that prevents proper digestion and can persist even after discontinuing medication Ileus (intestinal blockage): Added to FDA warning labels in September 2023 after post-marketing reports, this condition stops intestinal movement and can lead to life-threatening complications including infection and tissue death Intestinal obstruction and pseudo-obstruction: Physical or functional blockages requiring emergency hospitalization and often surgical intervention to prevent bowel perforation Chronic severe symptoms: Persistent vomiting, uncontrollable nausea, dangerous dehydration requiring IV fluids, and electrolyte imbalances necessitating repeated emergency department visits The FDAs decision to update warning labels demonstrates growing concern about these complications

2023;330(7):p

Patients should undergo baseline assessment including HbA1c and renal function

Garcia-Borreguero, D., Garcia-Malo, C., Granizo, J